Abstract
Peptidyl arginine deiminases (PADs) are a small group of isozymes that convert Arg residues on the surface of proteins into citrulline residues, typically as a part of posttranslational processing. PADs are present in most of the tissues, and the isozyme distribution is tissue-specific. In the past 15 years, it is becoming apparent that PADs are either upregulated or their catalytic activity is enhanced in certain disease conditions, including neurological diseases. In particular, hypercitrullinated proteins and elevated PAD activities are discovered in neurodegenerative conditions such as multiple sclerosis, Alzheimer’s disease etc. This review article reviews the status of PAD enzymes as targets in neurodegenerative conditions, and briefly outlines the efforts in medicinal chemistry to identify PAD inhibitors for the treatment of various neurodegenerative conditions.
Keywords: Peptidyl arginine deiminase, neurodegenerative diseases, citrullination, posttranslational modification.
Current Medicinal Chemistry
Title:Peptidyl Arginine Deiminases and Neurodegenerative Diseases
Volume: 23 Issue: 2
Author(s): R. Tu, H.M. Grover and L.P. Kotra
Affiliation:
Keywords: Peptidyl arginine deiminase, neurodegenerative diseases, citrullination, posttranslational modification.
Abstract: Peptidyl arginine deiminases (PADs) are a small group of isozymes that convert Arg residues on the surface of proteins into citrulline residues, typically as a part of posttranslational processing. PADs are present in most of the tissues, and the isozyme distribution is tissue-specific. In the past 15 years, it is becoming apparent that PADs are either upregulated or their catalytic activity is enhanced in certain disease conditions, including neurological diseases. In particular, hypercitrullinated proteins and elevated PAD activities are discovered in neurodegenerative conditions such as multiple sclerosis, Alzheimer’s disease etc. This review article reviews the status of PAD enzymes as targets in neurodegenerative conditions, and briefly outlines the efforts in medicinal chemistry to identify PAD inhibitors for the treatment of various neurodegenerative conditions.
Export Options
About this article
Cite this article as:
Tu R., Grover H.M. and Kotra L.P., Peptidyl Arginine Deiminases and Neurodegenerative Diseases, Current Medicinal Chemistry 2016; 23 (2) . https://dx.doi.org/10.2174/0929867323666151118120710
DOI https://dx.doi.org/10.2174/0929867323666151118120710 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Current Signal Transduction Therapy for Brain Tumors Review Article
Current Signal Transduction Therapy Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Adenosine Neuromodulation and Traumatic Brain Injury
Current Neuropharmacology Glycoxidation and Wound Healing in Diabetes: An Interesting Relationship
Current Diabetes Reviews Cardiac Dys-Synchronization and Arrhythmia in Hyperhomocysteinemia
Current Neurovascular Research Differentiation of High-grade Gliomas from Brain Metastases Using Tissue Similarity Maps (TSMs) Based Relative Cerebral Blood Volume Values
Current Medical Imaging Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?
Current Vascular Pharmacology COVID-19, Angiotensin-Converting Enzyme 2 and Renin-Angiotensin System Inhibition: Implications for Practice
Current Hypertension Reviews Pathogenesis of Stroke-Like Episodes in MELAS: Analysis of Neurovascular Cellular Mechanisms
Current Neurovascular Research Clinical and Forensic Signs Related to Opioids Abuse
Current Drug Abuse Reviews Activated Protein C: A Promising Drug with Multiple Effects?
Mini-Reviews in Medicinal Chemistry Lipid Nanocarriers (LNC) and their Applications in Ocular Drug Delivery
Current Medicinal Chemistry The Chemistry and Pharmacology of Tetrahydropyridines
Current Medicinal Chemistry Advances of Liquid Chromatographic Determination of Fumonisins; Potential Mycotoxins for Humans
Current Pharmaceutical Analysis The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Pharmacological Strategies that Affect HIF-1 in the Ischemic Brain: Focus on Hydroxylases Activity and Protein Kinase Pathways
Current Signal Transduction Therapy Melatonin and Its Therapeutic Potential in Neuroprotection
Central Nervous System Agents in Medicinal Chemistry Physical Therapy Modalities in Management of Fibromyalgia
Current Pharmaceutical Design Prevention of Ischemic Stroke: Antithrombotic Therapy in Cardiac Embolism
Current Drug Targets Natural Products Towards the Discovery of Potential Future Antithrombotic Drugs
Current Pharmaceutical Design